Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Apeiron Biologics
Apeiron Biologics
Activities:
Research & Development
X
LinkedIn
Trending Articles
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
Broughton receives flexible scope ISO 17025 accreditation
New certification allows accreditation without prior approval
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Research & Development
Expanding the medicinal chemist’s toolbox
Ray Boffey, Executive Director of Medicines Research at Domainex, explains the applications and benefits of fragment-based drug discovery, fragment hit expansion and the use of flow chemistry
Research & Development
Apeiron and Domainex partner to progress drug discovery
The companies have previously collaborated on hit identification, both fragment-based and virtual screening
Pharmaceutical
APEIRON appoints Peter Llewellyn-Davies as new CFO
Research & Development
Sanofi, Evotec and Apeiron Biologics to develop novel immuno-oncology treatments
Aim to bring together complementary expertise to identify and develop potential cancer treatments
Research & Development
Evotec and Apeiron establish pain alliance
Companies will identify small molecule modulators of DREAM
Subscribe now